1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level

Brain Research

Volumn 741, Issue 1-2, 1996, Pages 185-196

  Kupsch, Andreas ^a,b,e   Sautter, Jürgen ^a,b   Schwarz, Johannes ^a   Riederer, Peter ^d   Gerlach, Manfred ^d   Oertel, Wolfgang H ^a,b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Clinical Neurochemistry   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; calcium; common marmoset; N methyl 4 phenylpyridine; neurotoxicity; nimodipine; striatum; substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE; NIMODIPINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MARMOSET; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC AMINES; CALCIUM CHANNEL BLOCKERS; CALLITHRIX; DOPAMINE AGENTS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MPTP POISONING; NEOSTRIATUM; NIMODIPINE; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0030601952     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00917-1     Document Type: Article

References (59)

1. [1] Albanese, A., Granata, R., Gregori, B., Piccardi, P., Colosimo, C. and Tonali, P., Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates, Neuroscience, 55 (1993) 823-832.
2. [2] Azmitia, E.C., Nimodipine attenuates NMDA -and MDMA-induced toxicity of cultured fetal serotonergic neurons: evidence for a generic model of calcium toxicity. In J. Traber and W.H. Gispen (Eds.), Nimodipine and Central Nervous System Function: New Vistas, Schattauer-Verlag, Stuttgart, 1989, pp. 141-159.
3. [3] Benazzouz, A., Boraud, T., Dubétat, P., Boireau, A., Stutzman, J.-M. and Gross, C., Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study, Eur. J. Pharmacol. 284 (1995) 299-307.
4. [4] Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M. and Kopin, I.J., A primate model of parkinsonism: selective destruction of dopaminergic neuons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetryhydropyridine, Proc. Natl. Acad. Sci. USA, 80 (1983) 4546-4550.
5. + in the rat, Neurosci. Lett., 118 (1990) 151-154.
6. + selectively affects calcium homeostasis in mesencephalic cell cultures from embryonal C57/B16 mice, J. Neural Transm. Gen. Sect. 100 (1995) 153-163.
7. [7] Chiueh, C.C., Miyake, H., Huang, S.-J. and Peng, M.T., Role of extracellular calcium ion on 1-methyl-4-phenylpyridine induced sustained exocytosis of endogenous striatal dopamine in vivo, Eur. J. Pharmacol., 183 (1990) 1069-1070.
8. +, a novel voltage-regulated ion channel activator for dihydropyridine-sensitive L-type calcium channels on nigrostriatal terminals. Posters Neurosci., 1 (1991) 37-41.
9. [9] Davis, G.C., Williams, A.C., Markey, S.P., Ebert, M.H., Calne, E.D., Reichert, C.M. and Kopin, I.J., Chronic parkinsonism secondary to intravenous injection of meperidine analogues, Psychiatry Res., 1 (1979) 249-254.
10. 3H)nitrobenzylthioinosine binding to the adenosine transporter in human brain, Eur. J. Pharmacol., 238 (1993) 131-133.
11. 2+-channels, Neurosci. Lett., 145 (1992) 121-125.
12. [12] Erausquin, G.A., Costa, E. and Hanbauer, I., Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease, Pharmacol. Rev., 46 (1994) 467-482.
13. [13] Fadda, F., Gessa, G.L., Mosca, E. and Stefanini, E., Different effects of the calcium antagonists nimodipine and flunarizine on dopamine metabolism in the rat brain, J. Neural Transm., 75 (1989) 195-200.
14. [14] Finger, S. and Dunnett, S.M., Nimodipine enhances growth and vascularization of neural grafts, Exp. Neurol., 104 (1989) 1-9.
15. [15] Forno, L.S., DeLanney, L.E., Irwin, I. and Langston, J.W., Similarities and differences between MPTP-induced Parkinsonism and Parkinson's disease. Neuropathological considerations, Adv. Neurol., 60 (1993) 600-608.
16. +) together with 6-hydroxydopamine or dopamine stimulates Ca-release from mitochondria, FEBS Lett., 198 (1986) 99-102.
17. [17] Gerlach, M., Götz, M., Dirr, A., Kupsch, A., Janetzky, B., Oertel, W., Sautter, J., Schwarz, J., Reichmann, H. and Riederer, P., Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin, Neurochem. Int., 28 (1996) 41-49.
18. [18] Gerlach, M., Riederer, P., Przuntek, H. and Youdim, M.B.H., MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease, Eur. J. Pharmacol. Mol. Pharmacol. Sect., 208 (1991) 273-286.
19. [19] Gerlach, M., Russ, H., Winker, J., Witzmann, K., Traber, J., Stasch, J.-P., Riederer, P. and Przuntek, H., Effects of nimodipine on the 1-methyl-1-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice, Arzneim.-Forsch. / Drug Res., 43 (1993) 413-415.
20. D28k-containing cells, Ann. NY Acad. Sci., 648 (1992) 42-62.
21. [21] Harper, A.M., Craigen, L. and Kazda, S., Effect of the calcium antagonist, nimodipine, on cerebral blood flow and metabolism in the primate, J. Cereb. Blood Flow Metab., 1 (1981) 349-356.
22. [22] Hantraye, P., Varastet, M., Peschanski, M., Riche, D., Cesaro, P., Willer, J.C. and Maziere, M., Stable Parkinsonian syndrome and uneven loss of dopamine fibres following chronic MPTP administration in baboons, Neuroscience, 53 (1993) 169-178.
23. + within the monaminergic system of the primate brain following MPTP administration: an in vivo autoradiographic study, Neuroscience, 40 (1991) 133-158.
24. [24] Iacopino, A.M. and Christakos, S., Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative disease, Proc. Natl. Acad. Sci. USA, 87 (1990) 4078-4082
25. [25] Jackson-Lewis, V., Jakowec, M., Burke, R.E. and Przedborski, S., Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurodegeneration, 4 (1995) 257-269.
26. [26] Jenner, P., Rupniak, N.M.J., Rose, S., Kelley, E., Kilpatrick, G., Lees, A. and Marsden, C.D., 1-Methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced parkinsonism in the common marmoset, Neurosci. Lett., 50 (1984) 85-90.
27. [27] Johannessen, J.N., Chiueh, C.C., Burns, R.S. and Markey, S.P., Differences in metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects, Life Sci., 36 (1985) 219-224.
28. [28] Kass, G.E.N., Wright, J.M., Nicotera, P. and Orrenius, S., The mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, role of intracellular calcium, Arch. Biochem. Biophys., 260 (1988) 789-797.
29. [29] Kitt, C.A., Cork, L.C., Eidelberg, F., Joh, T.H. and Price, D.L., Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey, Neuroscience, 17 (1986) 1089-1103.
30. [30] Kopin, I.J. and Markey, S.P., MPTP-toxicity: implication of research in Parkinson's disease, Annu. Rev. Neurosci., 11 (1988) 81-96.
31. [31] Kupsch, A., Gerlach, M., Pupeter, S.C., Sautter, J., Dirr, A., Arnold, G., Opitz, W., Przuntek, H., Riederer, P. and Oertel, W.H., Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice, NeuroReport, 6 (1995) 621-625.
32. [32] Kupsch, A., Löschmann, P-A., Sauer, H., Arnold, G., Renner, P., Pufal, D., Burg, M., Wachtel, H., Ten Bruggencate, G. and Oertel, W.H., Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in a mouse model of Parkinson's disease, Brain Res., 592 (1992) 74-83.
33. [33] Lange, K.W., Löschmann, P-A., Sofic, E., Burg, M., Horowski, R., Kalveram, K.T., Wachtel, H. and Riederer, P., The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates, Naunyn-Schmiedeberg's Arch. Pharmacol., 348 (1993) 586-592.
34. [34] Langston, J.W., Ballard, P., Tetrud, J.W. and Irwin, I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219 (1983) 979-980.
35. [35] Langston, J.W., Forno, L.S., Rebert, C.S. and Irwin, I., Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey, Brain Res., 292 (1984) 390-394.
36. [36] Lavoie, B. and Parent, A., Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys, NeuroReport, 2 (1991) 601-604.
37. [37] Lemons, V.B., Chehrazi, B.B., Kauten, R., Hein L. and Wagner. F.C., The effect of nimodipine on high-energy phosphates and intracellular pH during cerebral ischemia, J. Neurotrauma, 10 (1993) 73-81.
38. [38] Marsden, C.D., Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 57 (1994) 672-681.
39. [39] Mercuri, N.B., Bonci, A., Calabresi, P., Stratta, F., Stefani, A. and Berandi, G., Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones, Br. J. Pharmacol., 113 (1994) 831-838.
40. [40] Micheli, F.E., Pardal, M.F., Giannaula, R., Gatto, M., Parera, I., Paradiso, G., Torres, M., Pikielny, R. and Pardal, J., Movement disorders and depression due to flunarizine and cinnarizine, Movement Disord., 4 (1989) 139-142.
41. [41] Mück, W. and Bode, H., Bioanalytics of nimodipine - an overview of methods, Pharmazie, 49 (1994) 130-139.
42. 3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease, Brain Res. 377 (1986) 186-189.
43. [43] Oertel, W.H. and Kupsch, A., Pathogenesis and animal studies of Parkinson's disease, Curr. Opin. Neurol. Neurosurg., 6 (1993) 323-332.
44. [44] Pérez-Otaño, I., Herrero, M.T., Oset, C., Ceballos, M.L., Luqin, M.R., Obeso, J.A. and Del Río, J., Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in common marmosets, Brain Res., 567 (1991) 127-132.
45. [45] Reinhard, J.F., Daniels, A.J. and Viveros, O.H., Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant, Neurosci. Lett., 90 (1988) 349-353.
46. [46] Scriabine, A., Schuurmann, T. and Traber, J., Pharmacological basis for the use of nimodipine in central nervous system disorders, FASEB J., 3 (1989) 1799-1806.
47. [47] Schneider, J.S. and Kovelowski, C.J., Chronic exposure to low doses of MPTP: I. Cognitive deficits motor asymptomatic monkeys, Brain Res. 519 (1990) 122-128.
48. [48] Seniuk, N.A., Tatton, W.G. and Greenwood, C. E., Dose-dependent destruction of the coeruleus-cortical and the nigrostriatal projections by MPTP, Brain Res., 527 (1990) 7-20.
49. +) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique, dependence on sodium but not calcium, Brain Res., 443 (1988) 101-116.
50. [50] Stephan, H., Baron, G. and Schwerdtfeger, W.K., The Brain of the Common Marmoset. A Stereotactic Atlas, Springer-Verlag, Berlin/Heidelberg/New York, 1980.
51. +, J. Neural Transm., 74 (1988) 75-86.
52. [52] Takada, M., Kono, T. and Kitai, S.T., Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons, Brain Res., 590 (1992) 311-315.
53. [53] Tatton, W.G., Kwan, M.M., Verrier, M.C., Seniuk, N.A. and Theriault, E., MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells, Brain Res., 527 (1990) 21-31.
54. + neurotoxicity, Nature 349 (1991) 414-418.
55. [55] Tomac, A., Lindquist, E., Lin, L.-F.H., Ogren, S.O., Young, D., Hoffer, B. and Olson, L., Protection and repair of nigrostriatal dopaminerigic system by GDNF in vivo, Nature, 373 (1995) 335-339.
56. [56] Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O. and Hashimoto, N., Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys, Neurosurgery, 37 (1995) 733-739.
57. [57] Watson, D.L, Carpenter, C.L., Marks, S.S. and Greenberg, D.A., Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease, Ann. Neurol., 23 (1988) 303-305.
58. [58] Yamada, T., McGeer, P.L., Baimbridge, K.G. and McGeer, E.G., Relative sparing in Parkinson's disease of substantia nigra neurons containing calbindin-D28K, Brain Res., 526 (1990) 303-307.
59. [59] Zuddas, A., Oberto, G., Vaglini, F., Fascetti, F., Forani, F. and Corsini, G.G., MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J. Neurochem., 59 (1992) 733-739.